125 related articles for article (PubMed ID: 18363031)
1. Association study of TP53 polymorphisms with lung cancer in a Korean population.
Jung HY; Whang YM; Sung JS; Shin HD; Park BL; Kim JS; Shin SW; Seo HY; Seo JH; Kim YH
J Hum Genet; 2008; 53(6):508. PubMed ID: 18363031
[TBL] [Abstract][Full Text] [Related]
2. Lack of association of fragile histidine triad (FHIT) polymorphisms with lung cancer in the Korean population.
Jung HY; Sung JS; Whang YM; Shin HD; Park BL; Kim JS; Shin SW; Seo HY; Sung HJ; Choi IK; Oh SC; Seo JH; Kim YH
J Hum Genet; 2007; 52(8):668. PubMed ID: 17609851
[TBL] [Abstract][Full Text] [Related]
3. TP53 Arg72Pro and XPD Lys751Gln Gene Polymorphisms and Risk of Lung Cancer in Bangladeshi Patients.
Nairuz T; Rahman M; Bushra MU; Kabir Y
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2091-2098. PubMed ID: 32711437
[TBL] [Abstract][Full Text] [Related]
4. TP53 common variants and interaction with PPP1R13L and CD3EAP SNPs and lung cancer risk and smoking behavior in a Chinese population.
Yin J; Hou W; Vogel U; Li X; Ma Y; Wang C; Wang H; Sun Z
Biomed J; 2022 Feb; 45(1):169-178. PubMed ID: 35351459
[TBL] [Abstract][Full Text] [Related]
5. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
Popanda O; Edler L; Waas P; Schattenberg T; Butkiewicz D; Muley T; Dienemann H; Risch A; Bartsch H; Schmezer P
Lung Cancer; 2007 Jan; 55(1):25-34. PubMed ID: 17059853
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
7. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors.
Mechanic LE; Bowman ED; Welsh JA; Khan MA; Hagiwara N; Enewold L; Shields PG; Burdette L; Chanock S; Harris CC
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):214-22. PubMed ID: 17301252
[TBL] [Abstract][Full Text] [Related]
8. Functional effect of polymorphisms in 15q25 locus on CHRNA5 mRNA, bulky DNA adducts and TP53 mutations.
Tekpli X; Landvik NE; Skaug V; Gulsvik A; Haugen A; Zienolddiny S
Int J Cancer; 2013 Apr; 132(8):1811-20. PubMed ID: 23011884
[TBL] [Abstract][Full Text] [Related]
9.
Cavic M; Spasic J; Krivokuca A; Boljevic I; Kuburovic M; Radosavljevic D; Jankovic R
J Clin Pathol; 2019 Jan; 72(1):75-80. PubMed ID: 30467244
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in XPD and TP53 and mutation in human lung cancer.
Mechanic LE; Marrogi AJ; Welsh JA; Bowman ED; Khan MA; Enewold L; Zheng YL; Chanock S; Shields PG; Harris CC
Carcinogenesis; 2005 Mar; 26(3):597-604. PubMed ID: 15564288
[TBL] [Abstract][Full Text] [Related]
11. Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer.
Cho S; Kim MJ; Choi YY; Yoo SS; Lee WK; Lee EJ; Jang EJ; Bae EY; Jin G; Jeon HS; Lee SY; Cha SI; Park TI; Kim CH; Park JY
Lung Cancer; 2011 Jul; 73(1):25-31. PubMed ID: 21129811
[TBL] [Abstract][Full Text] [Related]
12. Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants.
Deben C; Van den Bossche J; Van Der Steen N; Lardon F; Wouters A; de Beeck KO; Hermans C; Jacobs J; Peeters M; Van Camp G; Rolfo C; Deschoolmeester V; Pauwels P
Tumour Biol; 2017 Feb; 39(2):1010428317694327. PubMed ID: 28240049
[TBL] [Abstract][Full Text] [Related]
13. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in apoptosis-related genes and TP53 mutations in non-small cell lung cancer.
Bae EY; Lee EJ; Kang HG; Lee SY; Jin G; Lee WK; Choi JE; Jeon HS; Lim JO; Lee EB; Park JY
J Korean Med Sci; 2011 Nov; 26(11):1527-30. PubMed ID: 22065914
[TBL] [Abstract][Full Text] [Related]
15. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain.
Fernández-Rubio A; López-Cima MF; González-Arriaga P; García-Castro L; Pascual T; Marrón MG; Tardón A
Lung Cancer; 2008 Sep; 61(3):309-16. PubMed ID: 18336951
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutations in Korean patients with non-small cell lung cancer.
Lee EB; Jin G; Lee SY; Park JY; Kim MJ; Choi JE; Jeon HS; Cha SI; Cho S; Kim CH; Park TI; Jung TH; Son JW; Park JY
J Korean Med Sci; 2010 May; 25(5):698-705. PubMed ID: 20436704
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
[TBL] [Abstract][Full Text] [Related]
19. Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer.
Shipman R; Schraml P; Colombi M; Raefle G; Dalquen P; Ludwig C
Eur J Cancer; 1996 Feb; 32A(2):335-41. PubMed ID: 8664051
[TBL] [Abstract][Full Text] [Related]
20. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population.
Sreeja L; Syamala V; Raveendran PB; Santhi S; Madhavan J; Ankathil R
Cancer Invest; 2008 Feb; 26(1):41-6. PubMed ID: 18181044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
